Population Health Model Predicting the Long-Term Impact of Sotatercept on Morbidity and Mortality in Patients with Pulmonary Arterial Hypertension (PAH)

[1]  D. Badesch,et al.  Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension. , 2023, The New England journal of medicine.

[2]  S. Rosenkranz,et al.  Risk stratification and response to therapy in patients with pulmonary arterial hypertension and comorbidities: A COMPERA analysis. , 2022, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[3]  M. Humbert,et al.  Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension , 2022, European Respiratory Journal.

[4]  M. Humbert,et al.  2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. , 2022, European heart journal.

[5]  Steven D Briscoe,et al.  Sotatercept analog suppresses inflammation to reverse experimental pulmonary arterial hypertension , 2022, Scientific Reports.

[6]  S. Duval,et al.  Mortality in Pulmonary Arterial Hypertension in the Modern Era: Early Insights From the Pulmonary Hypertension Association Registry , 2022, Journal of the American Heart Association.

[7]  B. Cockrill,et al.  Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review. , 2022, JAMA.

[8]  S. Lanes,et al.  Real‐world treatment patterns, healthcare resource utilization, and cost among adults with pulmonary arterial hypertension in the United States , 2022, Pulmonary circulation.

[9]  H. Palevsky,et al.  Delphi consensus recommendation for optimization of pulmonary hypertension therapy focusing on switching from a phosphodiesterase 5 inhibitor to riociguat , 2022, Pulmonary circulation.

[10]  S. Rosenkranz,et al.  COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension , 2021, European Respiratory Journal.

[11]  M. Humbert,et al.  External validation of a refined four-stratum risk assessment score from the French pulmonary hypertension registry , 2021, European Respiratory Journal.

[12]  S. Rosenkranz,et al.  Temporal trends in pulmonary arterial hypertension: results from the COMPERA registry , 2021, European Respiratory Journal.

[13]  S. Mathai,et al.  Development of the Pulmonary Hypertension Functional Classification Self-Report: a patient version adapted from the World Health Organization Functional Classification measure , 2021, Health and Quality of Life Outcomes.

[14]  P. Clarke,et al.  Cost‐Effectiveness of Combination Therapy for Patients With Systemic Sclerosis–Related Pulmonary Arterial Hypertension , 2021, Journal of the American Heart Association.

[15]  Douglas S. Burgoyne.  Reducing economic burden and improving quality of life in pulmonary arterial hypertension. , 2021, The American journal of managed care.

[16]  W. Chung,et al.  United States Pulmonary Hypertension Scientific Registry (USPHSR): Baseline Characteristics. , 2020, Chest.

[17]  Gary M Besinque,et al.  The myth of the stable pulmonary arterial hypertension patient. , 2019, The American journal of managed care.

[18]  S. Kawut,et al.  New and Emerging Therapies for Pulmonary Arterial Hypertension. , 2019, Annual review of medicine.

[19]  Z. Jing,et al.  Risk stratification and medical therapy of pulmonary arterial hypertension , 2019, European Respiratory Journal.

[20]  N. Stockbridge,et al.  Clinical trial design and new therapies for pulmonary arterial hypertension , 2019, European Respiratory Journal.

[21]  Rowan Iskandar,et al.  A theoretical foundation for state-transition cohort models in health decision analysis , 2018, PloS one.

[22]  J. Bathon,et al.  Survival of adults with systemic autoimmune rheumatic diseases and pulmonary arterial hypertension after lung transplantation , 2018, Rheumatology.

[23]  A. Torbicki,et al.  Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality. , 2018, Journal of the American College of Cardiology.

[24]  M. Humbert,et al.  Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension , 2017, European Respiratory Journal.

[25]  Simon Gibbs,et al.  2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. , 2016, Revista espanola de cardiologia.

[26]  D. Coyle,et al.  Cost Effectiveness of First-Line Oral Therapies for Pulmonary Arterial Hypertension: A Modelling Study , 2016, PharmacoEconomics.

[27]  R. Benza,et al.  Five-Year outcomes of patients enrolled in the REVEAL Registry. , 2015, Chest.

[28]  Simon Gibbs,et al.  2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension , 2015, European Respiratory Journal.

[29]  M. Mcgoon,et al.  Characterization of First-Time Hospitalizations in Patients With Newly Diagnosed Pulmonary Arterial Hypertension in the REVEAL Registry , 2014, Chest.

[30]  L. Howard.  Prognostic factors in pulmonary arterial hypertension: assessing the course of the disease , 2011, European Respiratory Review.

[31]  H. Birnbaum,et al.  Prevalence of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension in the United States , 2011, Current medical research and opinion.

[32]  A. Zaiman,et al.  Outcomes of hospitalisation for right heart failure in pulmonary arterial hypertension , 2011, European Respiratory Journal.

[33]  H. Palevsky,et al.  Wide variation in clinicians' assessment of New York Heart Association/World Health Organization functional class in patients with pulmonary arterial hypertension. , 2009, Mayo Clinic proceedings.